Intellia Focuses on Pipeline Development Amid Stiff Competition
Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.
The rise and fall of the motorized selfie camera on Android
The motorized selfie camera proved to be a fleeting trend on smartphones. The rise of hole-punch cutouts and the ongoing development of under-display camera technology closed the door to a potential ...
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.